Affiliation:
1. Department of Internal Medicine Kaiser Permanente Los Angeles Medical Center Los Angeles California USA
2. Department of Hematology & Oncology Kaiser Permanente Los Angeles Medical Center Los Angeles California USA
Abstract
ABSTRACTBackgroundImmune checkpoint inhibitors (ICIs) have led to improved outcomes for many cancer types. However, their use can also precipitate immune‐related adverse events (irAEs) that can affect any organ system. While irAEs are often mild, they rarely affect multiple organ systems concurrently and can be fatal.CaseWe report a fatal case of myasthenia gravis, myositis, and cardiotoxicity overlap syndrome precipitated by the ICI pembrolizumab along with a brief review of available literature.ConclusionEarly recognition of high grade irAEs and prompt intervention is essential. Despite the poor prognosis of these overlap syndromes, current recommendations offer little guidance for severe cases and warrant a call for increased awareness and expansion of available therapeutics.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Multiple drugs;Reactions Weekly;2024-08-17